Genomic Testing Cooperative (GTC) and C2i Genomics Announce Collaboration to Offer Liquid Biopsy Testing for Staging and Monitoring Solid Tumors Based on Pattern Recognition of
GTC Solid Tumor Profile™ with 434 genes test is now covered by Medicare for patients with a wide range of solid tumor cancers Irvine, California–
(Click photo to download the pdf file)
Genomic Testing Cooperative to Present Data on its Proprietary RNA Profiling and Artificial Intelligence Algorithms at American Society of Hematology Annual Meeting Irvine, California– December
GTC featured in the Orange County Business Journal on September 30, 2019 [Click image to enlarge]
MDS is defined as ineffective hematopoiesis characterized by adequate or increased hematologic elements in bone marrow with peripheral cytopenia. Therefore, the presence of cytopenia in
GTC Receives Medicare Coverage for 2 NGS Hematology Molecular Profiling Tests Including Liquid Biopsy for Hematologic Neoplasms Irvine, California– June 19, 2019 – Genomic Testing
Genomic Testing cooperative (GTC) provides a comprehensive genomic profiling of breast cancer including evaluating: – Actional mutations – Gene amplification and deletion – Hormonal expression
(FOR UPDATED INFORMATION ABOUT COMPREHENSIVE TESTING FOR BREAST CANCER VISIT THIS PAGE: Comprehensive testing for breast cancer evaluating DNA and RNA) When you order GTC
The FDA has approved Balversa (erdafitinib) as a treatment for adult patients with locally advanced or metastatic bladder cancer that have FGFR3 or FGFR2 abnormalities
